From OncoWiki
Jump to: navigation, search

Indolent Non-Hodgkin's Lymphoma

Bendamustine 120 mg/m2 iv over 30-60 min d1 and 2
Q3w x up to 12 cycles


Friedberg JW et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204

Chronic Lymphocytic Leukemia

Bendamustine 100 mg/m2 iv over 30 min d1 and 2
Q4w x 6 cycles


Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.2007 ASH annual meeting. Abstract 2043

Mantle Cell Lymphoma and Indolent NHL

Bendamustine + Rituximab